Institut Gustave Roussy

Institut Gustave Roussy (IGR), located in Villejuif just south of Paris, is the leading cancer center in Europe and consistently ranked among the world's top cancer hospitals by international healthcare quality surveys. Founded in 1926, the institute was named after the French neurologist and cancer researcher Gustave Roussy and has dedicated nearly a century to the singular mission of fighting cancer through prevention, research, diagnosis, and treatment.

With more than 50,000 patients managed each year — approximately 3,800 of whom are new cancer cases — Gustave Roussy is not only France's largest cancer center but one of the highest-volume oncology institutions in the world. This scale of clinical activity translates directly into expertise: the institute's specialists manage every type of cancer across all age groups, including the rarest and most complex malignancies that cannot be adequately treated at general hospitals.

Gustave Roussy is a Comprehensive Cancer Centre (Centre de Lutte Contre le Cancer, CLCC) — one of only 20 such institutions in France — recognized by the French Ministry of Health for its integrated approach combining clinical care, research, and cancer prevention. The institute is also designated as a Cancer Research Site of Excellence (SIRIC) by French cancer research authorities, reflecting the quality and output of its research programs.

The institute's research mission is inseparable from its clinical care: Gustave Roussy is home to more than 1,000 researchers and research staff working on cancer biology, genetics, immunology, and therapeutic development. This creates a uniquely innovative clinical environment where the latest scientific discoveries translate rapidly into new treatments for patients, often through early-phase clinical trials that are not available elsewhere in France or internationally.

Gustave Roussy provides comprehensive oncological care across the full spectrum of cancer types, from the most common solid tumors to the rarest malignancies, treating both adult and pediatric patients through dedicated specialized programs.

Adult solid tumor oncology covers all major cancer sites: lung (including mesothelioma), breast, colorectal, gastric, pancreatic, liver and biliary, head and neck, genitourinary (prostate, bladder, kidney, testicular), gynecological (ovarian, uterine, cervical), thyroid, bone and soft tissue sarcomas, and skin cancers (including melanoma). Each tumor site is managed by a dedicated multidisciplinary team including medical oncologists, surgical oncologists, radiation oncologists, radiologists, and pathologists who collaborate at regular tumor boards.

Haematological malignancies form a major program: leukemia (AML, CML, ALL, CLL), lymphoma (Hodgkin's, non-Hodgkin's, primary CNS lymphoma), multiple myeloma, and myelodysplastic syndromes are all managed by dedicated hematologists with access to bone marrow and stem cell transplantation.

Pediatric oncology is a major strength, with dedicated programs for childhood leukemia, brain tumors, solid tumors (neuroblastoma, Wilms' tumor, rhabdomyosarcoma), and retinoblastoma, managed by a specialized pediatric oncology team with the full range of systemic and local therapies.

Clinical trials access is one of the most compelling reasons patients from France and internationally seek care at Gustave Roussy: the institute runs hundreds of active clinical trials at any time, offering access to novel immunotherapies, targeted agents, CAR-T cell therapies, and experimental treatment approaches that are not yet commercially available. Early-phase (Phase I and II) oncology trials are a particular speciality.

Gustave Roussy is located at 114 rue Edouard Vaillant in Villejuif, Val-de-Marne, directly south of Paris and accessible via RER B (Villejuif-Louis Aragon station) or by road from central Paris. The institute occupies a large, dedicated cancer campus that has expanded continuously over its nearly century-long history.

Inpatient capacity includes specialized oncology wards for medical oncology, surgical oncology, hematology, pediatric oncology, and bone marrow transplantation. A dedicated ICU provides critical care for oncological emergencies and post-surgical patients. Day hospital facilities for chemotherapy, targeted therapy, and immunotherapy infusion manage an enormous daily patient volume.

Surgical facilities at Gustave Roussy encompass the full range of cancer-directed surgery: robot-assisted surgery (da Vinci system) for urological, gynecological, and thoracic procedures, intraoperative radiotherapy (IORT) for specific cancers, cytoreductive surgery with HIPEC (hyperthermic intraperitoneal chemotherapy) for peritoneal malignancies, and microsurgical reconstruction for head and neck and other complex resections.

Radiation oncology technology at Gustave Roussy is among the most advanced in Europe: CyberKnife stereotactic radiosurgery, proton therapy (available at the ProtonTherapy Center), IMRT and IGRT with multiple linear accelerators, brachytherapy, and intraoperative radiotherapy. Diagnostic imaging for oncology is comprehensive: PET-CT, 3T MRI, CT with advanced reconstruction, and molecular imaging capabilities.

The research infrastructure includes dedicated laboratory buildings housing over 1,000 researchers in cancer biology, immunology, genetics, bioinformatics, and pharmaceutical sciences. A biobank of tumor samples and a clinical trials unit managing hundreds of simultaneous trials make Gustave Roussy one of the world's most productive cancer research environments.

Institut Gustave Roussy welcomes international patients from across the world who seek the benefit of its unique combination of world-leading cancer expertise, access to innovative clinical trials, and the quality assurance of Europe's pre-eminent cancer center. The institute has dedicated international patient services staff who coordinate care for overseas patients in multiple languages including English.

For international patients, the first step is typically submitting medical records and imaging for expert review by Gustave Roussy's multidisciplinary tumor board. This remote tumor board review allows specialists to assess the case and provide a treatment recommendation, enabling patients to make an informed decision before traveling to France. The turnaround for expert opinion is typically within two weeks of complete documentation receipt.

Once treatment is agreed, the international patient services team coordinates appointment scheduling, hospital admission, accommodation for accompanying family members (the institute has a patient lodge and relationships with nearby hotels), and liaison with international health insurers. Major international insurance plans are accepted, and self-paying patients receive detailed cost estimates.

Villejuif is accessible from Paris Orly Airport (approximately 20 minutes by road) and from Charles de Gaulle Airport (approximately 40-50 minutes). Paris's exceptional international connectivity makes Gustave Roussy accessible from any major city in the world. Patients from countries where the specific cancer type is not well managed locally frequently choose Gustave Roussy as their treatment destination.

Institut Gustave Roussy holds HAS (Haute Autorite de Sante) certification, France's national hospital quality accreditation, and is designated as a Comprehensive Cancer Centre (Centre de Lutte Contre le Cancer) by the French Ministry of Health. This designation reflects the institute's integrated approach to cancer care, research, and prevention, and is one of the most rigorous quality designations in French oncology.

The institute has been designated a SIRIC (Site de Recherche Integree sur le Cancer) by the French National Cancer Institute (INCa), recognizing the quality and productivity of its integrated clinical and translational research programs. This research designation comes with sustained government funding and periodic performance review.

Gustave Roussy is an ESMO-designated Designated Cancer Centre of Excellence by the European Society for Medical Oncology (ESMO), recognizing the excellence of its medical oncology clinical and research programs against European benchmarks. The institute is also a member of the Comprehensive Cancer Centers Alliance (CCCA) of leading European cancer centers.

In Newsweek's World's Best Hospitals annual rankings focused on oncology, Gustave Roussy has consistently ranked as one of the world's top cancer hospitals, including the top position globally. This ranking is validated by international surveys of oncology peers and patient outcomes data, representing independent external validation of Gustave Roussy's standing as the world leader in cancer care.